<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">BMC Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">BMC Neurosci</journal-id>
<journal-title-group>
<journal-title>BMC Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="epub">1471-2202</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27855659</article-id>
<article-id pub-id-type="pmc">5114760</article-id>
<article-id pub-id-type="publisher-id">308</article-id>
<article-id pub-id-type="doi">10.1186/s12868-016-0308-1</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>mTOR and MAPK: from localized translation control to epilepsy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Pernice</surname>
<given-names>Helena F.</given-names>
</name>
<address>
<email>Franziska.Pernice@med.uni-muenchen.de</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schieweck</surname>
<given-names>Rico</given-names>
</name>
<address>
<email>Rico.Schieweck@med.uni-muenchen.de</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kiebler</surname>
<given-names>Michael A.</given-names>
</name>
<address>
<email>Michael.Kiebler@med.uni-muenchen.de</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1517-695X</contrib-id>
<name>
<surname>Popper</surname>
<given-names>Bastian</given-names>
</name>
<address>
<phone>++49-89-2180 71996</phone>
<email>Bastian.Popper@med.uni-muenchen.de</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<aff id="Aff1">Department of Anatomy and Cell Biology, Biomedical Center (BMC), Medical Faculty, Ludwig-Maximilians-University (LMU), Großhaderner Straße 9, 82152 Planegg-Martinsried, Germany </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>17</day>
<month>11</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>17</day>
<month>11</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<volume>17</volume>
<elocation-id>73</elocation-id>
<history>
<date date-type="received">
<day>29</day>
<month>6</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>9</day>
<month>11</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2016</copyright-statement>
<license license-type="OpenAccess">
<license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<sec>
<title>Background</title>
<p>Epilepsy is one of the most common neurological diseases characterized by excessive hyperexcitability of neurons. Molecular mechanisms of epilepsy are diverse and not really understood. All in common is the misregulation of proteins that determine excitability such as potassium and sodium channels as well as GABA receptors; which are all known as biomarkers for epilepsy. Two recently identified key pathways involve the kinases mechanistic target of rapamycin (mTOR) and mitogen-activated protein kinases (MAPK). Interestingly, mRNAs coding for those biomarkers are found to be localized at or near synapses indicating a local misregulation of synthesis and activity.</p>
</sec>
<sec>
<title>Results</title>
<p>Research in the last decade indicates that RNA-binding proteins (RBPs) responsible for mRNA localization, stability and translation mediate local expression control. Among others, they are affected by mTOR and MAPK to guide expression of epileptic factors. These results suggest that mTOR/MAPK act on RBPs to regulate the fate of mRNAs, indicating a misregulation of protein expression at synapses in epilepsy.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>We propose that mTOR and MAPK regulate RBPs, thereby guiding the local expression of their target-mRNAs encoding for markers of epilepsy. Thus, misregulated mTOR/MAPK-RBP interplay may result in excessive local synthesis of ion channels and receptors thereby leading to hyperexcitability. Continuous stimulation of synapses further activates mTOR/MAPK pathway reinforcing their effect on RBP-mediated expression control establishing the basis for epilepsy. Here, we highlight findings showing the tight interplay between mTOR as well as MAPK with RBPs to control expression for epileptic biomarkers.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>RBP</kwd>
<kwd>mTOR</kwd>
<kwd>MAPK</kwd>
<kwd>ERK</kwd>
<kwd>Epilepsy</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008349</institution-id>
<institution>Boehringer Ingelheim</institution>
</institution-wrap>
</funding-source>
</award-group>
<award-group>
<funding-source>
<institution>FöFoLe LMU Munich</institution>
</funding-source>
</award-group>
<award-group>
<funding-source>
<institution>DFG (FOR 2333 TP08)</institution>
</funding-source>
</award-group>
<award-group>
<funding-source>
<institution>Friedrich-Baur-Stiftung LMU Munich</institution>
</funding-source>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2016</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Background</title>
<p>Epilepsy is one of the most common neurological diseases, affecting about 65 million people in the world [<xref ref-type="bibr" rid="CR1">1</xref>], therein 8.5 per 1000 population in the US [<xref ref-type="bibr" rid="CR2">2</xref>] and 18 per 1000 population in Europe [<xref ref-type="bibr" rid="CR3">3</xref>]. The disease affects life quality through discrimination and segregation of patients [<xref ref-type="bibr" rid="CR4">4</xref>]. Furthermore, therapies have high economic costs of up to $13.8 billion in Europe [<xref ref-type="bibr" rid="CR5">5</xref>]. Available therapies usually target symptoms and are still ineffective in 30% of all cases [<xref ref-type="bibr" rid="CR6">6</xref>]. It is commonly believed that abnormal synchronous firing in a hyperexcitable neuronal network results in epileptic seizures [<xref ref-type="bibr" rid="CR7">7</xref>]. Generally, epilepsy can be differentiated according to the region of its generation: Generalized seizures origin from both hemispheres, whereas focal epilepsy derives from one specific area of the brain, most commonly the temporal lobe or the limbic system, which results in temporal lobe epilepsy (TLE) [<xref ref-type="bibr" rid="CR8">8</xref>]. Idiopathic epilepsies that can take both generalized and focal forms, have a genetic or epigenetic cause, classifying genetic epilepsy as one specific group [<xref ref-type="bibr" rid="CR9">9</xref>]. In the last decade, immense effort was made to identify mutations ending up with a list of genetic risk factors causing epilepsy [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>] (Table <xref ref-type="table" rid="Tab1">1</xref>). In 40% of the cases, however, the etiology of epilepsy is unknown. This emphasizes the need for a better understanding of genetic causes forming the basis of putative therapies.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Epilepsy targets that are regulated by RBPs and dependent on mTOR/MAPK activity</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"></th><th align="left" rowspan="2">Effect</th><th align="left" rowspan="2">Pathway</th><th align="left" colspan="2">Epilepsy related targets</th><th align="left" rowspan="2">Link to epilepsy</th></tr><tr><th align="left">Gene</th><th align="left">Protein</th></tr></thead><tbody><tr><td align="left" rowspan="6">FMRP</td><td align="left" rowspan="6">Translational repression and dendritic RNA transport [<xref ref-type="bibr" rid="CR48">48</xref>]</td><td align="left">mTOR [<xref ref-type="bibr" rid="CR57">57</xref>–<xref ref-type="bibr" rid="CR61">61</xref>]</td><td align="left">
<italic>CaMKIIα</italic>
</td><td align="left">CaMKIIα [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]</td><td align="left" rowspan="3">Childhood seizures in patients and mice with FXS [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]</td></tr><tr><td align="left" rowspan="5">MAPK [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]</td><td align="left">
<italic>KCNC1</italic>
</td><td align="left">Kv3.1 [<xref ref-type="bibr" rid="CR52">52</xref>]</td></tr><tr><td align="left">
<italic>KCND2</italic>
</td><td align="left">Kv4.2 [<xref ref-type="bibr" rid="CR54">54</xref>]</td></tr><tr><td align="left">
<italic>CACNA1B</italic>
</td><td align="left">Cav2.2 [<xref ref-type="bibr" rid="CR53">53</xref>]</td><td align="left" rowspan="3">Audiogenic seizures in rats with FXS [<xref ref-type="bibr" rid="CR62">62</xref>]</td></tr><tr><td align="left">
<italic>KCNMA1</italic>
</td><td align="left">BK channel [<xref ref-type="bibr" rid="CR51">51</xref>]</td></tr><tr><td align="left">
<italic>KCNT1</italic>
</td><td align="left">Slack channel [<xref ref-type="bibr" rid="CR50">50</xref>]</td></tr><tr><td align="left" rowspan="3">HuD</td><td align="left">RNA stabilization</td><td align="left">mTOR [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR79">79</xref>]</td><td align="left">
<italic>CaMKIIα</italic>
</td><td align="left">CaMKIIα [<xref ref-type="bibr" rid="CR77">77</xref>]</td><td align="left" rowspan="2">Increased protein level in rats with kainate induced seizures [<xref ref-type="bibr" rid="CR70">70</xref>]</td></tr><tr><td align="left">Splicing control</td><td align="left" rowspan="2">MAPK [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]</td><td align="left">
<italic>KCNA1</italic>
</td><td align="left">Kv1.1 [<xref ref-type="bibr" rid="CR69">69</xref>]</td></tr><tr><td align="left">Neuronal differentiation and plasticity [<xref ref-type="bibr" rid="CR67">67</xref>]</td><td align="left">
<italic>GLS</italic>
</td><td align="left">Glutaminase [<xref ref-type="bibr" rid="CR73">73</xref>]</td><td align="left">Increased susceptibility to audiogenic seizures in mice [<xref ref-type="bibr" rid="CR28">28</xref>]</td></tr><tr><td align="left" rowspan="3">HuR</td><td align="left">RNA stabilization</td><td align="left" rowspan="3">MAPK [<xref ref-type="bibr" rid="CR82">82</xref>–<xref ref-type="bibr" rid="CR85">85</xref>]</td><td align="left" rowspan="3">
<italic>GAP-43</italic>
</td><td align="left" rowspan="3">GAP-43 [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]</td><td align="left" rowspan="3">Pentylenetetrazol-induced seizures in mice [<xref ref-type="bibr" rid="CR82">82</xref>]</td></tr><tr><td align="left">Splicing control [<xref ref-type="bibr" rid="CR86">86</xref>]</td></tr><tr><td align="left">Cellular stress response [<xref ref-type="bibr" rid="CR67">67</xref>]</td></tr><tr><td align="left">CREB</td><td align="left">Translational activator [<xref ref-type="bibr" rid="CR89">89</xref>]</td><td align="left">MAPK [<xref ref-type="bibr" rid="CR40">40</xref>]</td><td align="left">
<italic>Bdnf</italic>
</td><td align="left">BDNF [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR92">92</xref>]</td><td align="left">Epileptic seizures in animal models of epilepsy and human patients [<xref ref-type="bibr" rid="CR29">29</xref>]</td></tr></tbody></table><table-wrap-foot><p>RBPs, their general effect on gene expression, involvement in mTOR and/or MAPK pathways, their mRNA targets, and encoded proteins as well as their link to epilepsy in animal models and human patients are depicted</p></table-wrap-foot></table-wrap>
</p>
<p>The genetic risk factors that have been found are diverse and are involved in regulation of various pathways affecting cell death, morphology and neurogenesis. One aspect that is essential for all models of epileptogenesis is the dysregulation of synaptic function. This includes presynaptic vesicle release, postsynaptic receptor expression and ion channel expression, which have provided new approaches on therapy for epilepsy [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>].</p>
<p>Recently, it has been shown that the mechanistic target of rapamycin (mTOR) and mitogen-activated protein kinases (MAPK) are important regulators of synaptic excitability involved in cognitive impairment and epilepsy in animal models as well as human disease [<xref ref-type="bibr" rid="CR14">14</xref>–<xref ref-type="bibr" rid="CR16">16</xref>]. Those kinases regulate gene expression in neurons in a stimulus-dependent manner [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Both pathways can be activated i.e. by long-term potentiation (LTP), a process characterized by enhanced transmission between simultaneously activated synapses. Still, not all neuronal stimulation paradigms lead to the activation of both mTOR and MAPK pathways [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Further research is necessary to describe the exact mechanisms and kind of neuronal excitation that leads to hyperactivity. Regardless, multiple key studies show an effect of mTOR and MAPK on general expression control [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Remarkably, recent research has shown that both mTOR and MAPK also act locally to regulate protein expression at activated synapses [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Together, these findings provide new insight into the molecular mechanisms of epilepsy and explain how lack of pathway control results in seizures.</p>
</sec>
<sec id="Sec2">
<title>RNA-binding proteins: mediators of remote expression control</title>
<p>Research in the last decade has shown that RNA-binding proteins (RBPs) are essential regulators of protein expression. For local gene expression, it was shown that RBPs regulate gene expression in a spatially restricted manner. mRNAs sequester RBPs by binding motifs in their 3′-untranslated region (3′-UTR). 3′-UTRs of localized transcripts are generally longer and more complex harboring cis-acting sequence motifs and secondary structures as binding platforms. It is commonly believed that some RBPs form large RNA–protein complexes termed RNA granules. These granules are transported along the cytoskeleton to synapses [<xref ref-type="bibr" rid="CR23">23</xref>]. Upon stimulation, those particles are unpacked, the mRNA is released and locally translated. The process of remote expression control is mediated by RBPs. They control different steps of posttranscriptional regulation such as mRNA transport, translation and mRNA stability (reviewed in [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]). The synchronization of all three steps is a prerequisite for local protein expression. Therefore, translation regulators such as Pumilio2 (Pum2) are part of transport granules as it was shown for Staufen2 (Stau2) [<xref ref-type="bibr" rid="CR26">26</xref>]. The relevance of RBPs for the occurrence of neurological and neuropsychiatric diseases has risen in the last years. Both loss of function and gain of function mutations of RBPs result in epileptic phenotypes [<xref ref-type="bibr" rid="CR27">27</xref>–<xref ref-type="bibr" rid="CR29">29</xref>]. There is evidence that known epilepsy targets are under control of RBPs suggesting a local expression control of those mRNAs; probably at synapses. RBPs regulate mRNA distribution and protein synthesis of known epilepsy targets such as <italic>CaMKIIα</italic> or <italic>KCNA1</italic> encoding for the potassium channel Kv1.1, as well as multiple other ion channels [<xref ref-type="bibr" rid="CR30">30</xref>]. It is therefore tempting to postulate that any aberrant translational control of newly synthesized proteins for regulators of synaptic excitability, e.g. ion channels or receptors, leads to epilepsy.</p>
</sec>
<sec id="Sec3">
<title>Dysregulation of mTOR-mediated expression control leads to epileptic seizures</title>
<p>mTOR is a serine-threonine kinase that forms two protein complexes termed mTORC1 and mTORC2 [<xref ref-type="bibr" rid="CR31">31</xref>]. mTORC1 consists of five components: mTOR as active center, raptor, MLST8, PRAS40 and DEPTOR. It is generally believed that mTOR acts mainly on translation. As a central check point, mTORC1 senses both internal and external signals such as nutrient and growth factor availability as well as oxidative stress to guide protein synthesis. mTORC2 is a rapamycin insensitive complex that contributes to cell survival functions, metabolism, proliferation and actin polymerization [<xref ref-type="bibr" rid="CR31">31</xref>]. The exact role of mTORC2 in cellular signaling is still unclear. Several neuropathological diseases such as autism, depression and epilepsy have been linked to dysregulation of both complexes [<xref ref-type="bibr" rid="CR17">17</xref>].</p>
<p>mTOR is a major player in the generation of neuronal homeostasis. Important factors for its maintenance is the balance of GABAergic and glutamatergic signaling, both of which are regulated by mTOR signaling [<xref ref-type="bibr" rid="CR32">32</xref>]. Elevated activity of mTORC1 is implicated with increased neuronal excitability [<xref ref-type="bibr" rid="CR31">31</xref>]. The relevance of mTOR regarding temporal lobe epilepsy in animal models and patients has been rising in importance throughout the last decade [<xref ref-type="bibr" rid="CR33">33</xref>–<xref ref-type="bibr" rid="CR35">35</xref>]. Various genetic diseases displaying a grave epileptic phenotype, like tuberous sclerosis, phosphatase and tensine homolog (PTEN)-hamartoma tumor syndromes and fragile X mental retardation syndrome (FXS), are associated with dysregulation of mTOR expression and activity [<xref ref-type="bibr" rid="CR17">17</xref>]. Specifically, excessive mTOR signaling through a mutation in the tuberous sclerosis complex (TSC1/2) leads to hippocampal hyperexcitability linking mTOR with temporal lobe epilepsy [<xref ref-type="bibr" rid="CR36">36</xref>]. Seizures generated in the hippocampus have also been related to hyperactive mTOR signaling in a mouse model harboring <italic>PTEN</italic> mutations. Knock-out of PTEN leads to hyperactive mTOR causing seizures generated in the hippocampus, mimicking the epileptic phenotype of focal cortical dysplasia [<xref ref-type="bibr" rid="CR37">37</xref>]. Thus, controllability of excitability by mTOR is crucial to maintain balanced firing of neurons.</p>
</sec>
<sec id="Sec4">
<title>Expression control by the MAPK pathway: a regulator of epileptic biomarkers</title>
<p>The mitogen-activated protein kinase (MAPK) family consists of three pathways, the extracellular signal regulated kinase (ERK) pathway, the p38 pathway and C-Jun N-terminal kinases (JNK) pathway. All three are highly conserved serine-threonine kinases that respond to nutrition and growth factors availability as well as neuronal activation [<xref ref-type="bibr" rid="CR38">38</xref>]. ERK stimulates the expression of <italic>N</italic>-methyl-<sc>d</sc>-aspartate (NMDA) receptors causing synaptic excitability. This, in turn, leads to seizures [<xref ref-type="bibr" rid="CR38">38</xref>]. Moreover, the neuroprotective effect of NMDA injected in mice before seizure induction is diminished by inhibition of the MAPK pathway, further underlining the potential of MAPK to regulate neuronal excitability [<xref ref-type="bibr" rid="CR39">39</xref>]. Also the induction of mossy fiber sprouting, an effect causally associated with epileptogenesis, by the ERK/MAPK pathway has been shown in rats after traumatic brain injury [<xref ref-type="bibr" rid="CR40">40</xref>]. This further supports a role of MAPK pathway in epileptogenesis. Interestingly, MAPK responds to different seizures-inducing treatments: maximal electroshock seizures in mice [<xref ref-type="bibr" rid="CR41">41</xref>], kainate [<xref ref-type="bibr" rid="CR42">42</xref>], pilocarpine [<xref ref-type="bibr" rid="CR43">43</xref>] and pentylenetetrazole [<xref ref-type="bibr" rid="CR44">44</xref>] as well as dopamine D1 receptor (D<sub>1</sub>R) agonist [<xref ref-type="bibr" rid="CR45">45</xref>]. These findings suggest a role of MAPK in epileptogenesis.</p>
<p>Strikingly, there is evidence that also the MAPK pathway involves RBPs that are misregulated in epilepsy, like FMRP and HuR. In this context, kinases regulate those proteins and, therewith, their ability to control posttranscriptional gene expression [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR46">46</xref>].</p>
</sec>
<sec id="Sec5">
<title>mTOR and MAPK pathways control RBPs and thereby protein expression</title>
<p>Some of the RBPs mentioned above are guided by mTOR/MAPK. Thus, it has been suggested that mTOR/MAPK affect local gene expression by regulating RBPs. In this review, we will focus on the effect of mTOR and MAPK on RBPs linking local expression control with neuronal hyperexcitability in epilepsy. We focus on localized transcripts at or near synapses that encode for proteins causing epilepsy. In addition, we emphasize that RBPs (1) regulate expression of those epilepsy targets and (2) are involved in the mTOR and/or MAPK pathway (Fig. <xref ref-type="fig" rid="Fig1">1</xref>). Together, mTOR/MAPK mediated control of RBPs represent a novel mechanism of remote expression control. In the following paragraphs, we will focus on RBPs already shown to be regulated by the mTOR and/or MAPK pathway.<fig id="Fig1"><label>Fig. 1</label><caption><p>Venn diagram showing mTOR/MAPK mediated expression control via RBPs. Localized RNAs encoding for proteins involved in epilepsy are regulated by RBPs. Those, in turn, are guided by mTOR/MAPK</p></caption><graphic id="MO1" xlink:href="12868_2016_308_Fig1_HTML"></graphic></fig>
</p>
</sec>
<sec id="Sec6">
<title>FMRP</title>
<p>Mutations in the fragile X mental retardation gene (<italic>fmr1</italic>) coding for the translation regulator FMRP lead to activity-dependent misregulation of protein synthesis at synapses and can result in seizures [<xref ref-type="bibr" rid="CR27">27</xref>]. FMRP is an RBP involved in dendritic transport and translation control [<xref ref-type="bibr" rid="CR47">47</xref>], specifically as a translational repressor [<xref ref-type="bibr" rid="CR48">48</xref>]. It regulates the synthesis of calcium/calmodulin dependent protein kinase II alpha (CaMKIIα) that influences synaptic plasticity [<xref ref-type="bibr" rid="CR49">49</xref>], the expression of multiple ion channels [<xref ref-type="bibr" rid="CR50">50</xref>–<xref ref-type="bibr" rid="CR54">54</xref>] and can lead causes epilepsy in knock-out mutant mice [<xref ref-type="bibr" rid="CR55">55</xref>].</p>
<p>FMRP loss of function causes fragile X syndrome (FXS). Interestingly, FXS patients also suffer from seizures [<xref ref-type="bibr" rid="CR56">56</xref>]. Furthermore, there is supportive evidence for a role of FMRP in temporal lobe epilepsy: In patients with temporal lobe epilepsy and in rats treated with the seizure-inducing drug pilocarpine, the level of cytosolic FMRP binding protein (CYFIP1) is elevated [<xref ref-type="bibr" rid="CR57">57</xref>]. CYFIP is a protein expressed at synapses, displaying multiple functions like local regulation of actin cytoskeleton dynamics and dendritic spine morphology [<xref ref-type="bibr" rid="CR57">57</xref>]. Interestingly, morphological abnormalities resulting from overexpressed CYFP1 can be rescued by the mTOR inhibitor rapamycin [<xref ref-type="bibr" rid="CR58">58</xref>] linking mTOR activity with a direct FMRP interactor. Furthermore, it has been shown that elevated levels of phosphorylated mTOR is associated with decreased FMRP [<xref ref-type="bibr" rid="CR59">59</xref>]. Additionally, regulation of FMRP via the mTOR target p70-S6 kinase (S6K1) has been proposed [<xref ref-type="bibr" rid="CR60">60</xref>]. S6K1 phosphorylates FMRP and, thereby, it regulates its ability to repress translation. Surprisingly, the phosphorylation of FMRP has been reported to be mTOR independent [<xref ref-type="bibr" rid="CR61">61</xref>] indicating an indirect effect of mTOR on FMRP-mediated expression control. Together, these results suggest that FMRP and mTOR are influencing each other to fine-tune protein expression.</p>
<p>The MAPK pathway is generally activated upon neuron stimulation. Activation of glutamate receptors, i.e. NMDA receptors, plays an important role in the generation of hyperactive firing of neurons. In this respect, activation of the metabotropic glutamate receptor 5 (mGluR5) results in excessive protein production in <italic>fmr1</italic> knockdown mice [<xref ref-type="bibr" rid="CR20">20</xref>]. Interestingly, young FXS rats are susceptible to audiogenic seizures [<xref ref-type="bibr" rid="CR62">62</xref>]. One hypothesis states that elevated protein levels at synapses leads to seizures [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. In contrast, mGluR5 does not directly influence chemically induced epilepsy in rats [<xref ref-type="bibr" rid="CR64">64</xref>]. Inhibition of mGluR5 corrects symptoms of fragile X syndrome in adult mice and, importantly, reduces overactive ERK and mTOR signaling [<xref ref-type="bibr" rid="CR65">65</xref>]. Furthermore, a direct link has been suggested from mGluR5 activation to mTOR and MAPK pathways in modulating FMRP-mediated expression control [<xref ref-type="bibr" rid="CR66">66</xref>]. Importantly, the fragile X syndrome phenotype can be reversed by blocking ERK activity suggesting an interplay between FMRP and the ERK pathway [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Since FXS-patient also suffer from seizures, those results indicate also a possible link to epilepsy.</p>
</sec>
<sec id="Sec7">
<title>Hu protein family</title>
<p>Another group of RBPs connected to neurological disease is the Hu protein family (reviewed in [<xref ref-type="bibr" rid="CR67">67</xref>]). Hu proteins are related to the embryonic lethal abnormal vision protein family (Elav) and were first described in patients with paraneoplastic encephalomyelitis [<xref ref-type="bibr" rid="CR68">68</xref>]. These proteins are primarily responsible for neuronal differentiation, learning and memory, as well as long-term potentiation. They exert their RNA stabilizing function via three highly conserved RNA recognition motifs binding to AU-rich regions in the 3′-UTR, in the polyA tail [<xref ref-type="bibr" rid="CR68">68</xref>] and in the coding region [<xref ref-type="bibr" rid="CR69">69</xref>].</p>
<p>One member of the Hu family is HuD that regulates gene expression in neurons. HuD is upregulated after kainate-induced seizures in rats and shows activity dependent increase in protein levels in hippocampal neurons [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]. Additionally, HuD localizes in an activity dependent manner in dendrites and interacts with mTOR targets in KCl stimulated hippocampal neurons [<xref ref-type="bibr" rid="CR72">72</xref>]. DeBoer et al. showed that HuD knockout mice also show increased susceptibility to auditory seizures [<xref ref-type="bibr" rid="CR28">28</xref>]. Supportive for these findings are results from other groups indicating a role of HuD in the regulation of synaptic excitability by adjusting the cellular glutamate levels via translation control of the glutaminase [<xref ref-type="bibr" rid="CR73">73</xref>]. Unbalanced glutamate levels and related receptors are responsible for epileptogenesis [<xref ref-type="bibr" rid="CR74">74</xref>]. Work by Sosanya et al. indicates an antagonistic relationship between HuD and mTOR in regulating expression of the voltage-gated potassium channel 1.1 (K<sub>v</sub>1.1) expression [<xref ref-type="bibr" rid="CR69">69</xref>]. mTOR inhibition leads to degradation of HuD targets thereby increasing the concentration of free HuD molecules that are binding K<sub>v</sub>1.1 mRNA more efficiently. Hence, K<sub>v</sub>1.1 expression is increased upon mTOR-inhibition [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR69">69</xref>]. Low Kv1.1 levels are associated with increasing seizure frequency in kainate induced temporal lobe epilepsy in rats, correlating with high mTOR levels [<xref ref-type="bibr" rid="CR75">75</xref>].</p>
<p>HuD has been shown to control changes in synaptic plasticity via the local translation of synaptic proteins such as CaMKIIα [<xref ref-type="bibr" rid="CR76">76</xref>]. Recent reports point to the interplay of the mTOR pathway with HuD-mediated expression control guiding branch specific expression of CaMKIIα [<xref ref-type="bibr" rid="CR77">77</xref>]. Proper cellular and subcellular expression of CaMKIIα is crucial for neuronal excitability. Consequently, dysfunctions might contribute to epilepsy [<xref ref-type="bibr" rid="CR78">78</xref>].</p>
<p>Importantly, inhibition of the protein kinase B (Akt)/glycogen synthase kinase 3 (GSK3) pathway leads to changes in HuD and HuR protein levels [<xref ref-type="bibr" rid="CR76">76</xref>]. The GSK3 pathway therefore represents a link between the mTOR, Akt and MAPK pathways [<xref ref-type="bibr" rid="CR79">79</xref>]. This suggests an interplay in the control of HuD between the different kinases. Together, these findings indicate that mTOR is necessary to guide HuD-mediated expression control. CaMKIIα, K<sub>v</sub>1.1 and glutaminase mRNAs are known HuD targets influencing neuronal excitability. Disruption of HuD expression control results in hyperactivity and seizures.</p>
<p>Additionally, neuronal activity causes HuD to localize in dendrites and dendritic spine like protrusions in primary hippocampal neurons [<xref ref-type="bibr" rid="CR76">76</xref>]. Furthermore, it colocalizes with the eukaryotic translation initiation factor 4E (eIF4E) suggesting regulation of translation. Known as a target of mTOR mediated translation activation via 4E-binding protein (4EBP), elF4E is a point of convergence between the mTOR and the MAPK pathway. This was observed in mGluR dependent LTP. Activation of mGluR leads to ERK2 activation, which further phosphorylates and activates MAPK interacting kinase 2 (Mnk2) leading to eIF4E phosphorylation [<xref ref-type="bibr" rid="CR80">80</xref>]. mGluR activation also recruits the phosphoinositide 3-kinase (PI3K)/mTOR pathway [<xref ref-type="bibr" rid="CR81">81</xref>], releasing the 4E binding protein 2 (4EBP2) mediated inhibition of elF4E and promoting translation [<xref ref-type="bibr" rid="CR80">80</xref>].</p>
<p>HuR is another well-studied member of the Hu family and ubiquitously expressed. Activation of the MAPK pathway by anisomycin causes stabilization of survival motor neuron (SMN) mRNA by HuR [<xref ref-type="bibr" rid="CR82">82</xref>]. Furthermore, several studies reveal the MAPK pathway to regulate HuR [<xref ref-type="bibr" rid="CR82">82</xref>–<xref ref-type="bibr" rid="CR84">84</xref>]. In a mouse pentylenetetrazole model of epilepsy, HuR target mRNAs in the hippocampus were analyzed [<xref ref-type="bibr" rid="CR85">85</xref>]. Amongst them were identified genes encoding for mossy fiber sprouting and apoptosis, which contribute to epilepsy [<xref ref-type="bibr" rid="CR85">85</xref>]. In addition, <italic>GAP</italic>-<italic>43</italic> encoding for homonymous protein involved in axon growth is bound [<xref ref-type="bibr" rid="CR86">86</xref>] and stabilized by HuR [<xref ref-type="bibr" rid="CR76">76</xref>]. Importantly, GAP-43 is a marker for progressive epilepsy in patients with focal cortical dysplasia [<xref ref-type="bibr" rid="CR87">87</xref>].</p>
</sec>
<sec id="Sec8">
<title>CREB</title>
<p>cAMP response element binding protein (CREB) is a transcription activator [<xref ref-type="bibr" rid="CR88">88</xref>]. It has been shown that it is crucial for the induction of LTP [<xref ref-type="bibr" rid="CR89">89</xref>]. In a genome-wide microarray analysis of hippocampal tissue from patients with temporal lobe epilepsy, the protein kinase A (PKA)/CREB pathway appeared as one of the most enriched [<xref ref-type="bibr" rid="CR90">90</xref>]. In addition, activation of CREB appears to cause epilepsy in rodent and human models [<xref ref-type="bibr" rid="CR29">29</xref>]. Furthermore, CREB-regulated transcription coactivator 1 (CRTC1) has been shown to translocate into hippocampal nuclei following pilocarpine-induced status epilepticus [<xref ref-type="bibr" rid="CR91">91</xref>]. CREB does not only influence transcription in the nucleus, but also leads to cell wide supply of protein and mRNA that can localize to the synapse when the synapse has been tagged, thereby permitting LTP [<xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR89">89</xref>]. One transcript targeted by CREB is the brain derived neurotrophic factor (BDNF) [<xref ref-type="bibr" rid="CR92">92</xref>], which has been associated to temporal lobe epilepsy in many cases [<xref ref-type="bibr" rid="CR93">93</xref>] and may serve as a serum marker for epilepsy [<xref ref-type="bibr" rid="CR94">94</xref>].</p>
<p>It is interesting to note that the MAPK pathway is a known regulator of CREB [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR95">95</xref>]. Furthermore, the MAPK-CREB pathway induces mossy fiber reorganization after traumatic brain injury in rats, a characteristic feature of epileptogenesis [<xref ref-type="bibr" rid="CR40">40</xref>]. In the human neocortex of epilepsy patients, a specific ERK activation pattern was linked to CREB phosphorylation and followed by enhanced transcription of CREB targets such as <italic>BDNF</italic> [<xref ref-type="bibr" rid="CR96">96</xref>]. Additionally, increased synaptic density was observed in these layers linking synaptic morphology with CREB-induced <italic>BDNF</italic> transcription. Interestingly, it has been shown that BDNF induces synthesis of the early growth response factor 3 (EGR3) which regulates GABA receptors indicating a role of CREB in neuronal excitability [<xref ref-type="bibr" rid="CR96">96</xref>]. These results highlight the causal link of MAPK activation and its effect on RBP-mediated expression control.</p>
</sec>
<sec id="Sec9" sec-type="conclusion">
<title>Conclusions</title>
<p>It is generally believed that epilepsy results from hyperexcitability and synchronous firing of neurons [<xref ref-type="bibr" rid="CR7">7</xref>]. In the last decade, many biomarkers such as potassium and sodium channels as well as GABA receptors have been identified (Table <xref ref-type="table" rid="Tab1">1</xref>). Beside those, mTOR and MAPK also contribute to epileptogenesis. Very often they are key players of converging pathways. Nonetheless, the underlying molecular mechanism of hyperexcitability and, in consequence, synchronous firing remain elusive. Strikingly, it has been shown that transcripts encoding for some of epileptic biomarkers including <italic>mTOR</italic> are localized in dendrites. Additionally, RBPs, mediators of RNA localization and remote expression control, have been linked to epilepsy bridging mTOR signaling with spatially restricted expression. We propose that hyperactive mTOR and MAPK affect RBPs and RBP-mediated expression control locally (Fig. <xref ref-type="fig" rid="Fig2">2</xref>). Thereby, they influence transcript transport, stability and translation at or near synapses of RBP target mRNAs. Thus, increased, local expression of ion channels and receptors results in enhanced synaptic density of excitability regulating proteins and, eventually, in increased synaptic transmission. In turn, augmented synaptic stimulation further activates mTOR and MAPK. This spatially restricted misregulation of synaptic excitability may therefore represent an accelerator of synchronous, neuronal firing that eventually results in seizures. Thus, RBPs might represent a novel category of epileptic biomarkers that can help to diagnose epilepsy in patients. Furthermore, they also can serve as additional targets for therapeutics. However, future studies will elucidate their eligibility for diagnosis and therapy.<fig id="Fig2"><label>Fig. 2</label><caption><p>Model of mTOR and MAPK mediated RBP-dependent expression control. Regulation of spatially restricted protein expression is guided by RBPs. mTOR and MAPK both regulate RBPs. The kinases influence the ability of RBPs to control RNA stability and translation thereby affecting protein levels at the synapse. Misregulation of mTOR and MAPK pathways have been linked to epilepsy. We propose that disturbed regulation of local protein expression causes overburden levels of epilepsy factors resulting in hyperexcitability and eventually seizures</p></caption><graphic id="MO2" xlink:href="12868_2016_308_Fig2_HTML"></graphic></fig>
</p>
<p>In conclusion, remote expression control that is regulated by mTOR and MAPK provides new approaches to understand epilepsy at a molecular and cellular level. Here, mTOR possibly regulates RBPs, i.e. via direct phosphorylation, to guide their expression control abilities. This regulation of RBPs via mTOR may be affected by inhibiting drugs such as Rapamycin. A recent phase 3 study on Everolimus, a Rapamycin analog, shows a positive effect on therapy resistant focal epilepsy related to tuberous sclerosis [<xref ref-type="bibr" rid="CR97">97</xref>]. This points to a significant role of mTOR inhibitors in epilepsy, and suggests a potential for the therapy of epilepsy caused by RBP deficiency. Nevertheless, more insight is necessary to develop new diagnosis and therapy strategies for the treatment of epilepsy and to understand side effects of mTOR and MAPK inhibition [<xref ref-type="bibr" rid="CR98">98</xref>].</p>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>4EBP</term>
<def>
<p>4E binding protein</p>
</def>
</def-item>
<def-item>
<term>Akt</term>
<def>
<p>protein kinase B</p>
</def>
</def-item>
<def-item>
<term>BDNF</term>
<def>
<p>brain derived neurotrophic factor</p>
</def>
</def-item>
<def-item>
<term>BK channel</term>
<def>
<p>calcium activated potassium channel</p>
</def>
</def-item>
<def-item>
<term>CaMKIIα</term>
<def>
<p>calcium calmodulin dependent protein kinase II alpha</p>
</def>
</def-item>
<def-item>
<term>Cav2.2</term>
<def>
<p>voltage gated calcium channel 2.2</p>
</def>
</def-item>
<def-item>
<term>CREB</term>
<def>
<p>cAMP response element binding protein</p>
</def>
</def-item>
<def-item>
<term>CRTC1</term>
<def>
<p>CREB-regulated transcription coactivator 1</p>
</def>
</def-item>
<def-item>
<term>CYFIP1</term>
<def>
<p>cytosolic FMRP binding protein</p>
</def>
</def-item>
<def-item>
<term>EGR3</term>
<def>
<p>early growth response factor 3</p>
</def>
</def-item>
<def-item>
<term>eIF4E</term>
<def>
<p>eukaryotic translation initiation factor 4E</p>
</def>
</def-item>
<def-item>
<term>Elav</term>
<def>
<p>embryonic lethal abnormal vision protein family</p>
</def>
</def-item>
<def-item>
<term>ERK</term>
<def>
<p>extracellular signal regulated kinase</p>
</def>
</def-item>
<def-item>
<term>Fmr1</term>
<def>
<p>fragile X mental retardation gene</p>
</def>
</def-item>
<def-item>
<term>FXS</term>
<def>
<p>fragile X mental retardation syndrome</p>
</def>
</def-item>
<def-item>
<term>GABA</term>
<def>
<p>gamma-aminobutyric acid</p>
</def>
</def-item>
<def-item>
<term>GAP-43</term>
<def>
<p>growth associated protein 43</p>
</def>
</def-item>
<def-item>
<term>GSK3</term>
<def>
<p>glycogen synthase kinase 3</p>
</def>
</def-item>
<def-item>
<term>JNK</term>
<def>
<p>C-Jun-N-terminal kinase</p>
</def>
</def-item>
<def-item>
<term>Kv1.1</term>
<def>
<p>voltage-gated potassium channel 1.1</p>
</def>
</def-item>
<def-item>
<term>Kv3.1</term>
<def>
<p>voltage-gated potassium channel 3.1</p>
</def>
</def-item>
<def-item>
<term>Kv4.2</term>
<def>
<p>voltage-gated potassium channel 4.2</p>
</def>
</def-item>
<def-item>
<term>MAPK</term>
<def>
<p>mitogen-activated protein kinase</p>
</def>
</def-item>
<def-item>
<term>mTOR</term>
<def>
<p>mechanistic target of rapamycin</p>
</def>
</def-item>
<def-item>
<term>mGluR</term>
<def>
<p>metabotropic Glutamate receptor</p>
</def>
</def-item>
<def-item>
<term>NMDA</term>
<def>
<p>
<italic>N</italic>-methyl-<sc>d</sc>-aspartate</p>
</def>
</def-item>
<def-item>
<term>PI3K</term>
<def>
<p>phosphoinositide 3-kinase</p>
</def>
</def-item>
<def-item>
<term>PKA</term>
<def>
<p>protein kinase A</p>
</def>
</def-item>
<def-item>
<term>PTEN</term>
<def>
<p>phosphatase and tensine homolog</p>
</def>
</def-item>
<def-item>
<term>RBP</term>
<def>
<p>RNA binding protein</p>
</def>
</def-item>
<def-item>
<term>S6K</term>
<def>
<p>p70-S6 kinase</p>
</def>
</def-item>
<def-item>
<term>Slack channel</term>
<def>
<p>Slack sodium activated potassium channel</p>
</def>
</def-item>
<def-item>
<term>SMN</term>
<def>
<p>survival motor neuron</p>
</def>
</def-item>
<def-item>
<term>TLE</term>
<def>
<p>temporal lobe epilepsy</p>
</def>
</def-item>
<def-item>
<term>TSC</term>
<def>
<p>tuberous sclerosis complex</p>
</def>
</def-item>
</def-list>
</glossary>
<ack>
<title>Authors’ contributions</title>
<p>HFP, RS, MAK and BP wrote the manuscript. All authors read and approved the final manuscript.</p>
<sec id="FPar1">
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<sec id="FPar2">
<title>Funding</title>
<p>This work was supported by the Boehringer Ingelheim Fonds—BIF dedicated to RS, the Förderprogramm für Forschung und Lehre—FöFoLe PhD program of the LMU Munich (30/2015) dedicated to HFP, DFG (FOR 2333 TP08) dedicated to MAK and the Friedrich-Baur-Stiftung (02/14) dedicated to BP. The authors declare no competing financial interests.</p>
</sec>
</ack>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moshé</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Perucca</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ryvlin</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Tomson</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Epilepsy: new advances</article-title>
<source/>Lancet
          <year>2015</year>
<volume>385</volume>
<fpage>884</fpage>
<lpage>898</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(14)60456-6</pub-id>
<pub-id pub-id-type="pmid">25260236</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Helmers</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Thurman</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Durgin</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Pai</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Faught</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Descriptive epidemiology of epilepsy in the U.S. population: a different approach</article-title>
<source/>Epilepsia
          <year>2015</year>
<volume>26</volume>
<fpage>942</fpage>
<lpage>948</lpage>
<pub-id pub-id-type="doi">10.1111/epi.13001</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Forsgren</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Beghi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Õun</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sillanpää</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The epidemiology of epilepsy in Europe—a systematic review</article-title>
<source/>Eur J Neurol
          <year>2005</year>
<volume>12</volume>
<fpage>245</fpage>
<lpage>253</lpage>
<pub-id pub-id-type="doi">10.1111/j.1468-1331.2004.00992.x</pub-id>
<pub-id pub-id-type="pmid">15804240</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prilipko</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Saxena</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Boer</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Atlas: epilepsy care in the world</article-title>
<source/>Book
          <year>2005</year>
<volume>129</volume>
<fpage>91</fpage>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olesen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gustavsson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Svensson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wittchen</surname>
<given-names>HU</given-names>
</name>
<name>
<surname>Jönsson</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>The economic cost of brain disorders in Europe</article-title>
<source/>Eur J Neurol
          <year>2012</year>
<volume>19</volume>
<fpage>155</fpage>
<lpage>162</lpage>
<pub-id pub-id-type="doi">10.1111/j.1468-1331.2011.03590.x</pub-id>
<pub-id pub-id-type="pmid">22175760</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eadie</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Shortcomings in the current treatment of epilepsy</article-title>
<source/>Expert Rev Neurother
          <year>2012</year>
<volume>12</volume>
<fpage>1419</fpage>
<lpage>1427</lpage>
<pub-id pub-id-type="doi">10.1586/ern.12.129</pub-id>
<pub-id pub-id-type="pmid">23237349</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scharfman</surname>
<given-names>HE</given-names>
</name>
</person-group>
<article-title>The neurobiology of epilepsy</article-title>
<source/>Curr Neurol Neurosci Rep
          <year>2007</year>
<volume>7</volume>
<fpage>348</fpage>
<lpage>354</lpage>
<pub-id pub-id-type="doi">10.1007/s11910-007-0053-z</pub-id>
<pub-id pub-id-type="pmid">17618543</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Badawy</surname>
<given-names>RAB</given-names>
</name>
<name>
<surname>Curatolo</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Newton</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Berkovic</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Macdonell</surname>
<given-names>RAL</given-names>
</name>
</person-group>
<article-title>Changes in cortical excitability differentiate generalized and focal epilepsy</article-title>
<source/>Ann Neurol
          <year>2007</year>
<volume>61</volume>
<fpage>324</fpage>
<lpage>331</lpage>
<pub-id pub-id-type="doi">10.1002/ana.21087</pub-id>
<pub-id pub-id-type="pmid">17358004</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shorvon</surname>
<given-names>SD</given-names>
</name>
</person-group>
<article-title>The etiologic classification of epilepsy</article-title>
<source/>Epilepsia
          <year>2011</year>
<volume>52</volume>
<fpage>1052</fpage>
<lpage>1057</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2011.03041.x</pub-id>
<pub-id pub-id-type="pmid">21449936</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<mixed-citation publication-type="other">Crino PB. mTOR signaling in epilepsy: insights from malformations of cortical development. Cold Spring Harb Perspect Med 2015;5(4). doi:10.1101/cshperspect.a022442.</mixed-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allen</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Berkovic</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Cossette</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Delanty</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Dlugos</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Eichler</surname>
<given-names>EE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo mutations in epileptic encephalopathies</article-title>
<source/>Nature
          <year>2013</year>
<volume>501</volume>
<fpage>217</fpage>
<lpage>221</lpage>
<pub-id pub-id-type="doi">10.1038/nature12439</pub-id>
<pub-id pub-id-type="pmid">23934111</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Snowball</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schorge</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Changing channels in pain and epilepsy: exploiting ion channel gene therapy for disorders of neuronal hyperexcitability</article-title>
<source/>FEBS Lett
          <year>2015</year>
<volume>589</volume>
<fpage>1620</fpage>
<lpage>1634</lpage>
<pub-id pub-id-type="doi">10.1016/j.febslet.2015.05.004</pub-id>
<pub-id pub-id-type="pmid">25979170</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Casillas-Espinosa</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Powell</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>O’Brien</surname>
<given-names>TJ</given-names>
</name>
</person-group>
<article-title>Regulators of synaptic transmission: roles in the pathogenesis and treatment of epilepsy</article-title>
<source/>Epilepsia
          <year>2012</year>
<volume>53</volume>
<fpage>41</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12034</pub-id>
<pub-id pub-id-type="pmid">23216578</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Krab</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Goorden</surname>
<given-names>SMI</given-names>
</name>
</person-group>
<source/>Elgersma Y
          <year>2008</year>
<publisher-loc>Trends Genet</publisher-loc>
<publisher-name>Oncogenes on my mind: ERK and MTOR signaling in cognitive diseases</publisher-name>
<fpage>498</fpage>
<lpage>510</lpage>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gorter</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Iyer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>White</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Colzi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>van Vliet</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Sisodiya</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hippocampal subregion-specific microRNA expression during epileptogenesis in experimental temporal lobe epilepsy</article-title>
<source/>Neurobiol Dis
          <year>2014</year>
<volume>62</volume>
<fpage>508</fpage>
<lpage>520</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2013.10.026</pub-id>
<pub-id pub-id-type="pmid">24184920</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M-X</given-names>
</name>
<name>
<surname>Swank</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Kunz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>G-Y</given-names>
</name>
</person-group>
<article-title>Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways</article-title>
<source/>J Neurosci
          <year>2005</year>
<volume>25</volume>
<fpage>11288</fpage>
<lpage>11299</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2284-05.2005</pub-id>
<pub-id pub-id-type="pmid">16339024</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lipton</surname>
<given-names>JO</given-names>
</name>
<name>
<surname>Sahin</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The neurology of mTOR</article-title>
<source/>Neuron
          <year>2014</year>
<volume>84</volume>
<fpage>275</fpage>
<lpage>291</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2014.09.034</pub-id>
<pub-id pub-id-type="pmid">25374355</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chotiner</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Nielson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Farris</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lewandowski</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Banos</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Assessment of the role of MAP kinase in mediating activity-dependent transcriptional activation of the immediate early gene Arc/Arg3.1 in the dentate gyrus in vivo</article-title>
<source/>Learn Mem
          <year>2010</year>
<volume>17</volume>
<fpage>117</fpage>
<lpage>129</lpage>
<pub-id pub-id-type="doi">10.1101/lm.1585910</pub-id>
<pub-id pub-id-type="pmid">20154358</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Auerbach</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Osterweil</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Bear</surname>
<given-names>MF</given-names>
</name>
</person-group>
<article-title>Mutations causing syndromic autism define an axis of synaptic pathophysiology</article-title>
<source/>Nature
          <year>2011</year>
<volume>480</volume>
<fpage>63</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="doi">10.1038/nature10658</pub-id>
<pub-id pub-id-type="pmid">22113615</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Osterweil</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Krueger</surname>
<given-names>DD</given-names>
</name>
<name>
<surname>Reinhold</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bear</surname>
<given-names>MF</given-names>
</name>
</person-group>
<article-title>Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome</article-title>
<source/>J Neurosci
          <year>2010</year>
<volume>30</volume>
<fpage>15616</fpage>
<lpage>15627</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3888-10.2010</pub-id>
<pub-id pub-id-type="pmid">21084617</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raab-Graham</surname>
<given-names>KF</given-names>
</name>
<name>
<surname>Haddick</surname>
<given-names>PCG</given-names>
</name>
<name>
<surname>Jan</surname>
<given-names>YN</given-names>
</name>
<name>
<surname>Jan</surname>
<given-names>LY</given-names>
</name>
</person-group>
<article-title>Activity- and mTOR-dependent suppression of Kv1.1 channel mRNA translation in dendrites</article-title>
<source/>Science
          <year>2006</year>
<volume>314</volume>
<fpage>144</fpage>
<lpage>148</lpage>
<pub-id pub-id-type="doi">10.1126/science.1131693</pub-id>
<pub-id pub-id-type="pmid">17023663</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kelleher</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Govindarajan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>H-Y</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tonegawa</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Translational control by MAPK signaling in long-term synaptic plasticity and memory</article-title>
<source/>Cell
          <year>2004</year>
<volume>116</volume>
<fpage>467</fpage>
<lpage>479</lpage>
<pub-id pub-id-type="doi">10.1016/S0092-8674(04)00115-1</pub-id>
<pub-id pub-id-type="pmid">15016380</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Köhrmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kaether</surname>
<given-names>C</given-names>
</name>
<name>
<surname>DesGroseillers</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Dotti</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Kiebler</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Microtubule-dependent recruitment of Staufen-green fluorescent protein into large RNA-containing granules and subsequent dendritic transport in living hippocampal neurons</article-title>
<source/>Mol Biol Cell
          <year>1999</year>
<volume>10</volume>
<fpage>2945</fpage>
<lpage>2953</lpage>
<pub-id pub-id-type="doi">10.1091/mbc.10.9.2945</pub-id>
<pub-id pub-id-type="pmid">10473638</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doyle</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kiebler</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Mechanisms of dendritic mRNA transport and its role in synaptic tagging</article-title>
<source/>EMBO J
          <year>2011</year>
<volume>30</volume>
<fpage>3540</fpage>
<lpage>3552</lpage>
<pub-id pub-id-type="doi">10.1038/emboj.2011.278</pub-id>
<pub-id pub-id-type="pmid">21878995</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jung</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gkogkas</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Sonenberg</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Holt</surname>
<given-names>CE</given-names>
</name>
</person-group>
<article-title>Remote control of gene function by local translation</article-title>
<source/>Cell
          <year>2014</year>
<volume>157</volume>
<fpage>26</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2014.03.005</pub-id>
<pub-id pub-id-type="pmid">24679524</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kiebler</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>DesGroseillers</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Molecular insights into mRNA transport and local translation in the mammalian nervous system</article-title>
<source/>Neuron
          <year>2000</year>
<volume>25</volume>
<fpage>19</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="doi">10.1016/S0896-6273(00)80868-5</pub-id>
<pub-id pub-id-type="pmid">10707969</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramocki</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Zoghbi</surname>
<given-names>HY</given-names>
</name>
</person-group>
<article-title>Failure of neuronal homeostasis results in common neuropsychiatric phenotypes</article-title>
<source/>Nature
          <year>2008</year>
<volume>455</volume>
<fpage>912</fpage>
<lpage>918</lpage>
<pub-id pub-id-type="doi">10.1038/nature07457</pub-id>
<pub-id pub-id-type="pmid">18923513</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DeBoer</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Azevedo</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Vega</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Brodkin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Akamatsu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Okano</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prenatal deletion of the RNA-binding protein HuD disrupts postnatal cortical circuit maturation and behavior</article-title>
<source/>J Neurosci
          <year>2014</year>
<volume>34</volume>
<fpage>3674</fpage>
<lpage>3686</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3703-13.2014</pub-id>
<pub-id pub-id-type="pmid">24599466</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Blendy</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>BE</given-names>
</name>
</person-group>
<article-title>Decreased CREB levels suppress epilepsy</article-title>
<source/>Neurobiol Dis
          <year>2012</year>
<volume>45</volume>
<fpage>253</fpage>
<lpage>263</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2011.08.009</pub-id>
<pub-id pub-id-type="pmid">21867753</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swanger</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Bassell</surname>
<given-names>GJ</given-names>
</name>
</person-group>
<article-title>Dendritic protein synthesis in the normal and diseased brain</article-title>
<source/>Neuroscience
          <year>2013</year>
<volume>232</volume>
<fpage>106</fpage>
<lpage>127</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2012.12.003</pub-id>
<pub-id pub-id-type="pmid">23262237</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laplante</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sabatini</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>mTOR signaling in growth control and disease</article-title>
<source/>Cell
          <year>2012</year>
<volume>149</volume>
<fpage>274</fpage>
<lpage>293</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2012.03.017</pub-id>
<pub-id pub-id-type="pmid">22500797</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weston</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Swann</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Multiple roles for mammalian target of rapamycin signaling in both glutamatergic and GABAergic synaptic transmission</article-title>
<source/>J Neurosci
          <year>2012</year>
<volume>32</volume>
<fpage>11441</fpage>
<lpage>11452</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1283-12.2012</pub-id>
<pub-id pub-id-type="pmid">22895726</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname>
<given-names>L-H</given-names>
</name>
<name>
<surname>Rensing</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy</article-title>
<source/>J Neurosci
          <year>2009</year>
<volume>29</volume>
<fpage>6964</fpage>
<lpage>6972</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0066-09.2009</pub-id>
<pub-id pub-id-type="pmid">19474323</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Bi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rapamycin suppresses the recurrent excitatory circuits of dentate gyrus in a mouse model of temporal lobe epilepsy</article-title>
<source/>Biochem Biophys Res Commun
          <year>2012</year>
<volume>420</volume>
<fpage>199</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2012.02.143</pub-id>
<pub-id pub-id-type="pmid">22414694</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tee</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Fingar</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Manning</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Kwiatkowski</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Cantley</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Blenis</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2002</year>
<volume>99</volume>
<fpage>13571</fpage>
<lpage>13576</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.202476899</pub-id>
<pub-id pub-id-type="pmid">12271141</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bateup</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Denefrio</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Saulnier</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Kornacker</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sabatini</surname>
<given-names>BL</given-names>
</name>
</person-group>
<article-title>Excitatory/inhibitory synaptic imbalance leads to hippocampal hyperexcitability in mouse models of tuberous sclerosis</article-title>
<source/>Neuron
          <year>2013</year>
<volume>78</volume>
<fpage>510</fpage>
<lpage>522</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2013.03.017</pub-id>
<pub-id pub-id-type="pmid">23664616</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsushita</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sakai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shimmura</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shigeto</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nishio</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Akamine</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sanefuji</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ishizaki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Torisu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nakabeppu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Takada</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Hyperactive mTOR signals in the proopiomelanocortin-expressing hippocampal neurons cause age- dependent epilepsy and premature death in mice</article-title>
<source/>Sci Rep
          <year>2016</year>
<volume>6</volume>
<fpage>1</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1038/s41598-016-0001-8</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nateri</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Raivich</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gebhardt</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Da Costa</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Naumann</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Vreugdenhil</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>ERK activation causes epilepsy by stimulating NMDA receptor activity</article-title>
<source/>EMBO J
          <year>2007</year>
<volume>26</volume>
<fpage>4891</fpage>
<lpage>4901</lpage>
<pub-id pub-id-type="doi">10.1038/sj.emboj.7601911</pub-id>
<pub-id pub-id-type="pmid">17972914</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Araújo</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Vandresen-Filho</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Martins</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Boeck</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Tasca</surname>
<given-names>CI</given-names>
</name>
</person-group>
<article-title>NMDA preconditioning protects against quinolinic acid-induced seizures via PKA, PI3K and MAPK/ERK signaling pathways</article-title>
<source/>Behav Brain Res
          <year>2011</year>
<volume>219</volume>
<fpage>92</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2010.12.025</pub-id>
<pub-id pub-id-type="pmid">21185872</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bramlett</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sick</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Alonso</surname>
<given-names>OF</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Changes in trkB-ERK1/2-CREB/Elk-1 pathways in hippocampal mossy fiber organization after traumatic brain injury</article-title>
<source/>J Cereb Blood Flow Metab
          <year>2004</year>
<volume>24</volume>
<fpage>934</fpage>
<lpage>943</lpage>
<pub-id pub-id-type="doi">10.1097/01.WCB.0000125888.56462.A1</pub-id>
<pub-id pub-id-type="pmid">15362724</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gangarossa</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sakkaki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lory</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Valjent</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Mouse hippocampal phosphorylation footprint induced by generalized seizures: focus on ERK, mTORC1 and Akt/GSK-3 pathways</article-title>
<source/>Neuroscience
          <year>2015</year>
<volume>311</volume>
<fpage>474</fpage>
<lpage>483</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2015.10.051</pub-id>
<pub-id pub-id-type="pmid">26545981</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crespo-Biel</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Canudas</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Camins</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pallàs</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Kainate induces AKT, ERK and cdk5/GSK3β pathway deregulation, phosphorylates tau protein in mouse hippocampus</article-title>
<source/>Neurochem Int
          <year>2007</year>
<volume>50</volume>
<fpage>435</fpage>
<lpage>442</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuint.2006.10.002</pub-id>
<pub-id pub-id-type="pmid">17116346</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Houser</surname>
<given-names>CR</given-names>
</name>
</person-group>
<article-title>Activation of ERK by spontaneous seizures in neural progenitors of the dentate gyrus in a mouse model of epilepsy</article-title>
<source/>Exp Neurol
          <year>2010</year>
<volume>224</volume>
<fpage>133</fpage>
<lpage>145</lpage>
<pub-id pub-id-type="doi">10.1016/j.expneurol.2010.03.003</pub-id>
<pub-id pub-id-type="pmid">20226181</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ben</surname>
<given-names>J</given-names>
</name>
<name>
<surname>de Oliveira</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Gonçalves</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Peres</surname>
<given-names>TV</given-names>
</name>
<name>
<surname>Matheus</surname>
<given-names>FC</given-names>
</name>
<name>
<surname>Hoeller</surname>
<given-names>AA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effects of pentylenetetrazole kindling on mitogen-activated protein kinases levels in neocortex and hippocampus of mice</article-title>
<source/>Neurochem Res
          <year>2014</year>
<volume>39</volume>
<fpage>2492</fpage>
<lpage>2500</lpage>
<pub-id pub-id-type="doi">10.1007/s11064-014-1453-5</pub-id>
<pub-id pub-id-type="pmid">25316496</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gangarossa</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Di Benedetto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>O’Sullivan</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Dunleavy</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Alcacer</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bonito-Oliva</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Convulsant doses of a dopamine D1 receptor agonist result in erk-dependent increases in Zif268 and Arc/Arg3.1 expression in mouse dentate gyrus</article-title>
<source/>PLoS One.
          <year>2011</year>
<volume>6</volume>
<fpage>e19415</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0019415</pub-id>
<pub-id pub-id-type="pmid">21559295</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Venigalla</surname>
<given-names>RKC</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>RNA-binding proteins as a point of convergence of the PI3K and p38 MAPK pathways</article-title>
<source/>Front Immunol
          <year>2012</year>
<volume>3</volume>
<fpage>398</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2012.00398</pub-id>
<pub-id pub-id-type="pmid">23272005</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Bassell</surname>
<given-names>GJ</given-names>
</name>
</person-group>
<source/>Warren ST
          <year>2008</year>
<publisher-loc>Neuron</publisher-loc>
<publisher-name>Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function</publisher-name>
<fpage>201</fpage>
<lpage>214</lpage>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Darnell</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Van Driesche</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hung</surname>
<given-names>KYS</given-names>
</name>
<name>
<surname>Mele</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fraser</surname>
<given-names>CE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism</article-title>
<source/>Cell
          <year>2011</year>
<volume>146</volume>
<fpage>247</fpage>
<lpage>261</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2011.06.013</pub-id>
<pub-id pub-id-type="pmid">21784246</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robison</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Emerging role of CaMKII in neuropsychiatric disease</article-title>
<source/>Trends Neurosci
          <year>2014</year>
<volume>37</volume>
<fpage>653</fpage>
<lpage>662</lpage>
<pub-id pub-id-type="doi">10.1016/j.tins.2014.07.001</pub-id>
<pub-id pub-id-type="pmid">25087161</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Kronengold</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gazula</surname>
<given-names>V-R</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Strumbos</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Sigworth</surname>
<given-names>FJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Fragile X mental retardation protein controls gating of the sodium-activated potassium channel Slack</article-title>
<source/>Nat Neurosci
          <year>2010</year>
<volume>13</volume>
<fpage>819</fpage>
<lpage>821</lpage>
<pub-id pub-id-type="doi">10.1038/nn.2563</pub-id>
<pub-id pub-id-type="pmid">20512134</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname>
<given-names>PY</given-names>
</name>
<name>
<surname>Rotman</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Blundon</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cavalli</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<article-title>FMRP regulates neurotransmitter release and synaptic information transmission by modulating action potential duration via BK channels</article-title>
<source/>Neuron
          <year>2013</year>
<volume>77</volume>
<fpage>696</fpage>
<lpage>711</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2012.12.018</pub-id>
<pub-id pub-id-type="pmid">23439122</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferron</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Fragile X mental retardation protein controls ion channel expression and activity</article-title>
<source/>J. Physiol.
          <year>2016</year>
<volume>594</volume>
<fpage>5861</fpage>
<lpage>5867</lpage>
<pub-id pub-id-type="doi">10.1113/JP270675</pub-id>
<pub-id pub-id-type="pmid">26864773</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferron</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Nieto-Rostro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cassidy</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Dolphin</surname>
<given-names>AC</given-names>
</name>
</person-group>
<article-title>Fragile X mental retardation protein controls synaptic vesicle exocytosis by modulating N-type calcium channel density</article-title>
<source/>Nat Commun
          <year>2014</year>
<volume>5</volume>
<fpage>3628</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms4628</pub-id>
<pub-id pub-id-type="pmid">24709664</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gross</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Pong</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Jeromin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bassell</surname>
<given-names>GJ</given-names>
</name>
</person-group>
<article-title>Fragile X mental retardation protein regulates protein expression and mRNA translation of the potassium channel Kv4.2</article-title>
<source/>J Neurosci
          <year>2011</year>
<volume>31</volume>
<fpage>5693</fpage>
<lpage>5698</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.6661-10.2011</pub-id>
<pub-id pub-id-type="pmid">21490210</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butler</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Abeliovich</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tonegawa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>McNamara</surname>
<given-names>JO</given-names>
</name>
</person-group>
<article-title>Limbic epilepsy in transgenic mice carrying a Ca<sup>2+</sup>/calmodulin-dependent kinase II alpha-subunit mutation</article-title>
<source/>Proc Natl Acad Sci USA
          <year>1995</year>
<volume>92</volume>
<fpage>6852</fpage>
<lpage>6855</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.92.15.6852</pub-id>
<pub-id pub-id-type="pmid">7624331</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagerman</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Stafstrom</surname>
<given-names>CE</given-names>
</name>
</person-group>
<article-title>Origins of epilepsy in fragile X syndrome</article-title>
<source/>Epilepsy Curr.
          <year>2009</year>
<volume>9</volume>
<fpage>108</fpage>
<lpage>112</lpage>
<pub-id pub-id-type="doi">10.1111/j.1535-7511.2009.01309.x</pub-id>
<pub-id pub-id-type="pmid">19693328</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Up-regulated cytoplasmic FMRP-interacting protein 1 in intractable temporal lobe epilepsy patients and a rat model</article-title>
<source/>Int J Neurosci
          <year>2015</year>
<volume>126</volume>
<fpage>542</fpage>
<lpage>551</lpage>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oguro-Ando</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rosensweig</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Herman</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Nishimura</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Werling</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bill</surname>
<given-names>BR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased CYFIP1 dosage alters cellular and dendritic morphology and dysregulates mTOR</article-title>
<source/>Mol Psychiatry.
          <year>2014</year>
<volume>20</volume>
<fpage>1069</fpage>
<lpage>1078</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2014.124</pub-id>
<pub-id pub-id-type="pmid">25311365</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hoeffer</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Takayasu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Miyawaki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>McBride</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Klann</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Dysregulation of mTOR signaling in fragile X syndrome</article-title>
<source/>J Neurosci
          <year>2010</year>
<volume>30</volume>
<fpage>694</fpage>
<lpage>702</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3696-09.2010</pub-id>
<pub-id pub-id-type="pmid">20071534</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Narayanan</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Nalavadi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Nakamoto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ceman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bassell</surname>
<given-names>GJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>S6K1 phosphorylates and regulates FMRP with the neuronal protein synthesis-dependent mTOR signaling cascade</article-title>
<source/>J Biol Chem
          <year>2008</year>
<volume>283</volume>
<fpage>18478</fpage>
<lpage>18482</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.C800055200</pub-id>
<pub-id pub-id-type="pmid">18474609</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartley</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>O’Keefe</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Bordey</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>FMRP S499 is phosphorylated independent of mTORC1-S6K1 activity</article-title>
<source/>PLoS One.
          <year>2014</year>
<volume>9</volume>
<fpage>e96956</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0096956</pub-id>
<pub-id pub-id-type="pmid">24806451</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curia</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gualtieri</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bartolomeo</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Vezzali</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Biagini</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Resilience to audiogenic seizures is associated with p-ERK1/2 dephosphorylation in the subiculum of Fmr1 knockout mice</article-title>
<source/>Front Cell Neurosci
          <year>2013</year>
<volume>7</volume>
<fpage>46</fpage>
<pub-id pub-id-type="doi">10.3389/fncel.2013.00046</pub-id>
<pub-id pub-id-type="pmid">23630463</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muddashetty</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Kelić</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gross</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bassell</surname>
<given-names>GJ</given-names>
</name>
</person-group>
<article-title>Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome</article-title>
<source/>J Neurosci
          <year>2007</year>
<volume>27</volume>
<fpage>5338</fpage>
<lpage>5348</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0937-07.2007</pub-id>
<pub-id pub-id-type="pmid">17507556</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Witkin</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Baez</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Eiler</surname>
<given-names>WJA</given-names>
</name>
</person-group>
<article-title>mGlu5 receptor deletion does not confer seizure protection to mice</article-title>
<source/>Life Sci
          <year>2008</year>
<volume>83</volume>
<fpage>377</fpage>
<lpage>380</lpage>
<pub-id pub-id-type="doi">10.1016/j.lfs.2008.07.001</pub-id>
<pub-id pub-id-type="pmid">18675825</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michalon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sidorov</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ballard</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Ozmen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Spooren</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Wettstein</surname>
<given-names>JG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice</article-title>
<source/>Neuron
          <year>2012</year>
<volume>74</volume>
<fpage>49</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2012.03.009</pub-id>
<pub-id pub-id-type="pmid">22500629</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santoro</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Bray</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>ST</given-names>
</name>
</person-group>
<article-title>Molecular mechanisms of fragile X syndrome: a twenty-year perspective</article-title>
<source/>Annu Rev Pathol Mech Dis
          <year>2012</year>
<volume>7</volume>
<fpage>219</fpage>
<lpage>245</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-pathol-011811-132457</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hinman</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Lou</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Diverse molecular functions of Hu proteins</article-title>
<source/>Cell Mol Life Sci
          <year>2008</year>
<volume>65</volume>
<fpage>3168</fpage>
<lpage>3181</lpage>
<pub-id pub-id-type="doi">10.1007/s00018-008-8252-6</pub-id>
<pub-id pub-id-type="pmid">18581050</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perrone-Bizzozero</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bird</surname>
<given-names>CW</given-names>
</name>
</person-group>
<article-title>Role of HuD in nervous system function and pathology</article-title>
<source/>Front. Biosci
          <year>2013</year>
<volume>5</volume>
<fpage>554</fpage>
<lpage>563</lpage>
<pub-id pub-id-type="doi">10.2741/S389</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sosanya</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>PPC</given-names>
</name>
<name>
<surname>Cacheaux</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Perrone-Bizzozero</surname>
<given-names>NI</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Degradation of high affinity HuD targets releases Kv1.1 mRNA from miR-129 repression by mTORC1</article-title>
<source/>J Cell Biol
          <year>2013</year>
<volume>202</volume>
<fpage>53</fpage>
<lpage>69</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.201212089</pub-id>
<pub-id pub-id-type="pmid">23836929</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Winden</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Karsten</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Bragin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kudo</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Gehman</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ruidera</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A systems level, functional genomics analysis of chronic epilepsy</article-title>
<source/>PLoS One.
          <year>2011</year>
<volume>6</volume>
<fpage>e20763</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0020763</pub-id>
<pub-id pub-id-type="pmid">21695113</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bolognani</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Contente-Cuomo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Perrone-Bizzozero</surname>
<given-names>NI</given-names>
</name>
</person-group>
<article-title>Novel recognition motifs and biological functions of the RNA-binding protein HuD revealed by genome-wide identification of its targets</article-title>
<source/>Nucleic Acids Res
          <year>2009</year>
<volume>38</volume>
<fpage>117</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkp863</pub-id>
<pub-id pub-id-type="pmid">19846595</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tiruchinapalli</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Caron</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Keene</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Activity-dependent expression of ELAV/Hu RBPs and neuronal mRNAs in seizure and cocaine brain</article-title>
<source/>J Neurochem
          <year>2008</year>
<volume>107</volume>
<fpage>1529</fpage>
<lpage>1543</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2008.05718.x</pub-id>
<pub-id pub-id-type="pmid">19014379</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ince-Dunn</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Okano</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>WY</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ule</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuronal Elav-like (Hu) proteins regulate RNA splicing and abundance to control glutamate levels and neuronal excitability</article-title>
<source/>Neuron
          <year>2012</year>
<volume>75</volume>
<fpage>1067</fpage>
<lpage>1079</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2012.07.009</pub-id>
<pub-id pub-id-type="pmid">22998874</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qian</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>FR</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamate receptors and interacting proteins in epileptogenesis</article-title>
<source/>Curr Neuropharmacol.
          <year>2016</year>
<volume>14</volume>
<fpage>551</fpage>
<lpage>562</lpage>
<pub-id pub-id-type="doi">10.2174/1570159X14666160331142228</pub-id>
<pub-id pub-id-type="pmid">27030135</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sosanya</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Brager</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Wolfe</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Niere</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Raab-Graham</surname>
<given-names>KF</given-names>
</name>
</person-group>
<article-title>Rapamycin reveals an mTOR-independent repression of Kv1.1 expression during epileptogenesis</article-title>
<source/>Neurobiol Dis
          <year>2015</year>
<volume>73</volume>
<fpage>96</fpage>
<lpage>105</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2014.09.011</pub-id>
<pub-id pub-id-type="pmid">25270294</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tiruchinapalli</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Ehlers</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Keene</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Activity-dependent expression of RNA binding protein HuD and its association with mRNAs in neurons</article-title>
<source/>RNA Biol
          <year>2008</year>
<volume>5</volume>
<fpage>157</fpage>
<lpage>168</lpage>
<pub-id pub-id-type="doi">10.4161/rna.5.3.6782</pub-id>
<pub-id pub-id-type="pmid">18769135</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<mixed-citation publication-type="other">Sosanya NM, Cacheaux LP, Workman ER, Niere F, Perrone-Bizzozero NI, Raab-Graham KF. Mammalian Target of Rapamycin (mTOR) Tagging Promotes Dendritic Branch Variability through the Capture of Ca<sup>2+</sup>/calmodulin-dependent protein kinase IIα (CaMKIIα)mRNAs by the RNA-binding Protein HuD. J Biol Chem. 2015;jbc.M114.599399.</mixed-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X-B</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>KD</given-names>
</name>
</person-group>
<article-title>Neuronal excitability and calcium/calmodulin-dependent protein kinase type II: location, location, location</article-title>
<source/>Epilepsia
          <year>2012</year>
<volume>53</volume>
<issue>Suppl 1</issue>
<fpage>45</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2012.03474.x</pub-id>
<pub-id pub-id-type="pmid">22612808</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Frame</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>The renaissance of GSK3</article-title>
<source/>Nat Rev Mol Cell Biol
          <year>2001</year>
<volume>2</volume>
<fpage>769</fpage>
<lpage>776</lpage>
<pub-id pub-id-type="doi">10.1038/35096075</pub-id>
<pub-id pub-id-type="pmid">11584304</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Banko</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Poulin</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Sonenberg</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Klann</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Regulation of eukaryotic initiation factor 4E by converging signaling pathways during metabotropic glutamate receptor-dependent long-term depression</article-title>
<source/>J Neurosci
          <year>2006</year>
<volume>26</volume>
<fpage>2167</fpage>
<lpage>2173</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.5196-05.2006</pub-id>
<pub-id pub-id-type="pmid">16495443</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hou</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Klann</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression</article-title>
<source/>J Neurosci
          <year>2004</year>
<volume>24</volume>
<fpage>6352</fpage>
<lpage>6361</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0995-04.2004</pub-id>
<pub-id pub-id-type="pmid">15254091</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farooq</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Balabanian</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Holcik</surname>
<given-names>M</given-names>
</name>
<name>
<surname>MacKenzie</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>p38 Mitogen-activated protein kinase stabilizes SMN mRNA through RNA binding protein HuR</article-title>
<source/>Hum Mol Genet
          <year>2009</year>
<volume>18</volume>
<fpage>4035</fpage>
<lpage>4045</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddp352</pub-id>
<pub-id pub-id-type="pmid">19648294</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lafarga</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Cuadrado</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lopez de Silanes</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bengoechea</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fernandez-Capetillo</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Nebreda</surname>
<given-names>AR</given-names>
</name>
</person-group>
<article-title>p38 Mitogen-activated protein kinase- and HuR-dependent stabilization of p21(Cip1) mRNA mediates the G(1)/S checkpoint</article-title>
<source/>Mol Cell Biol
          <year>2009</year>
<volume>29</volume>
<fpage>4341</fpage>
<lpage>4351</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.00210-09</pub-id>
<pub-id pub-id-type="pmid">19528229</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tiedje</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ronkina</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tehrani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dhamija</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Laass</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Holtmann</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The p38/MK2-driven exchange between tristetraprolin and HuR regulates AU-rich element-dependent translation</article-title>
<source/>PLoS Genet.
          <year>2012</year>
<volume>8</volume>
<fpage>e1002977</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1002977</pub-id>
<pub-id pub-id-type="pmid">23028373</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Westmark</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Gourronc</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Bartleson</surname>
<given-names>VB</given-names>
</name>
<name>
<surname>Sayin</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Bhattacharya</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sutula</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>HuR mRNA ligands expressed after seizure</article-title>
<source/>J Neuropathol Exp Neurol
          <year>2005</year>
<volume>64</volume>
<fpage>1037</fpage>
<lpage>1045</lpage>
<pub-id pub-id-type="doi">10.1097/01.jnen.0000189835.71574.e1</pub-id>
<pub-id pub-id-type="pmid">16319714</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brennan</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Steitz</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>HuR and mRNA stability</article-title>
<source/>Cell Mol Life Sci
          <year>2001</year>
<volume>58</volume>
<fpage>266</fpage>
<lpage>277</lpage>
<pub-id pub-id-type="doi">10.1007/PL00000854</pub-id>
<pub-id pub-id-type="pmid">11289308</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ying</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Najm</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Nemes</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Paula Pinheiro-Martins</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Alexopoulos</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gonzalez-Martinez</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Growth-associated protein 43 and progressive epilepsy in cortical dysplasia</article-title>
<source/>Ann Clin Transl Neurol
          <year>2014</year>
<volume>1</volume>
<fpage>453</fpage>
<lpage>461</lpage>
<pub-id pub-id-type="doi">10.1002/acn3.69</pub-id>
<pub-id pub-id-type="pmid">25356416</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lonze</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Ginty</surname>
<given-names>DD</given-names>
</name>
</person-group>
<article-title>Function and regulation of CREB family transcription factors in the nervous system</article-title>
<source/>Neuron
          <year>2002</year>
<volume>35</volume>
<fpage>605</fpage>
<lpage>623</lpage>
<pub-id pub-id-type="doi">10.1016/S0896-6273(02)00828-0</pub-id>
<pub-id pub-id-type="pmid">12194863</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barco</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Alarcon</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Kandel</surname>
<given-names>ER</given-names>
</name>
</person-group>
<article-title>Expression of constitutively active CREB protein facilitates the late phase of long-term potentiation by enhancing synaptic capture</article-title>
<source/>Cell
          <year>2002</year>
<volume>108</volume>
<fpage>689</fpage>
<lpage>703</lpage>
<pub-id pub-id-type="doi">10.1016/S0092-8674(02)00657-8</pub-id>
<pub-id pub-id-type="pmid">11893339</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mirza</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Appleton</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Burn</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Carr</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Crooks</surname>
<given-names>D</given-names>
</name>
<name>
<surname>du Plessis</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identifying the biological pathways underlying human focal epilepsy: from complexity to coherence to centrality</article-title>
<source/>Hum Mol Genet
          <year>2015</year>
<volume>24</volume>
<fpage>4306</fpage>
<lpage>4316</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddv163</pub-id>
<pub-id pub-id-type="pmid">25941323</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dubey</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>CRTC1 nuclear localization in the hippocampus of the pilocarpine-induced status epilepticus model of temporal lobe epilepsy</article-title>
<source/>Neuroscience
          <year>2016</year>
<volume>320</volume>
<fpage>57</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2016.01.059</pub-id>
<pub-id pub-id-type="pmid">26844388</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tao</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Finkbeiner</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Arnold</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Shaywitz</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>ME</given-names>
</name>
</person-group>
<article-title>Ca<sup>2+</sup> influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism</article-title>
<source/>Neuron
          <year>1998</year>
<volume>20</volume>
<fpage>709</fpage>
<lpage>726</lpage>
<pub-id pub-id-type="doi">10.1016/S0896-6273(00)81010-7</pub-id>
<pub-id pub-id-type="pmid">9581763</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martínez-Levy</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Rocha</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lubin</surname>
<given-names>FD</given-names>
</name>
<name>
<surname>Alonso-Vanegas</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Nani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Buentello-García</surname>
<given-names>RM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased expression of BDNF transcript with exon VI in hippocampi of patients with pharmaco-resistant temporal lobe epilepsy</article-title>
<source/>Neuroscience
          <year>2016</year>
<volume>314</volume>
<fpage>12</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2015.11.046</pub-id>
<pub-id pub-id-type="pmid">26621122</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hong</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sander</surname>
<given-names>JW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Serum brain-derived neurotrophic factor levels in epilepsy</article-title>
<source/>Eur J Neurol
          <year>2014</year>
<volume>21</volume>
<fpage>57</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="doi">10.1111/ene.12232</pub-id>
<pub-id pub-id-type="pmid">23879572</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xing</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ginty</surname>
<given-names>DD</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>ME</given-names>
</name>
</person-group>
<article-title>Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase</article-title>
<source/>Science
          <year>1996</year>
<volume>273</volume>
<fpage>959</fpage>
<lpage>963</lpage>
<pub-id pub-id-type="doi">10.1126/science.273.5277.959</pub-id>
<pub-id pub-id-type="pmid">8688081</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beaumont</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kapatos</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Loeb</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Layer-specific CREB target gene induction in human neocortical epilepsy</article-title>
<source/>J Neurosci
          <year>2012</year>
<volume>32</volume>
<fpage>14389</fpage>
<lpage>14401</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3408-12.2012</pub-id>
<pub-id pub-id-type="pmid">23055509</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<label>97.</label>
<mixed-citation publication-type="other">French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet [Internet]. 2016. doi:10.1016/S0140-6736(16)31419-2.</mixed-citation>
</ref>
<ref id="CR98">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sadowski</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kotuslka</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jóźwiak</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Management of side effects of mTOR inhibitors in tuberous sclerosis patients</article-title>
<source/>Pharmacol Rep
          <year>2016</year>
<volume>68</volume>
<fpage>536</fpage>
<lpage>542</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharep.2016.01.005</pub-id>
<pub-id pub-id-type="pmid">26891243</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>